PL441261A1 - Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania - Google Patents

Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania

Info

Publication number
PL441261A1
PL441261A1 PL441261A PL44126122A PL441261A1 PL 441261 A1 PL441261 A1 PL 441261A1 PL 441261 A PL441261 A PL 441261A PL 44126122 A PL44126122 A PL 44126122A PL 441261 A1 PL441261 A1 PL 441261A1
Authority
PL
Poland
Prior art keywords
bisphosphonate
formulation
calcium phosphate
lecithin
carrier
Prior art date
Application number
PL441261A
Other languages
English (en)
Inventor
Michał Wojasiński
Jolanta CZERSKA-DUSZAK
Joanna Latocha
Artur Małolepszy
Tomasz CIACH
Original Assignee
Politechnika Warszawska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Warszawska filed Critical Politechnika Warszawska
Priority to PL441261A priority Critical patent/PL441261A1/pl
Priority to PCT/IB2023/055336 priority patent/WO2023228105A1/en
Publication of PL441261A1 publication Critical patent/PL441261A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Abstract

Przedmiotem zgłoszenia jest formulacja nanocząstek fosforanu wapnia, korzystnie hydroksyapatytu, modyfikowanych lecytyną, korzystnie fosfatydylocholiną, o zwiększonym wychwycie komórkowym jako nośnik bisfosfonianu, charakteryzująca się tym że bisfosfonian jest wybrany z grupy leków-bisfosfonianów dopuszczonych do zastosowań medycznych obejmującej alendronian oraz zoledronian, bisfosfonian jest enkapsulowany w nanocząstkach fosforanu wapnia w ilości do 40% masowych a nanocząstki mają rozmiar poniżej 200 nm. Przedmiotem zgłoszenia jest również sposób otrzymywania formulacji.
PL441261A 2022-05-24 2022-05-24 Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania PL441261A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL441261A PL441261A1 (pl) 2022-05-24 2022-05-24 Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania
PCT/IB2023/055336 WO2023228105A1 (en) 2022-05-24 2023-05-24 Formulation of lecithin-modified calcium phosphate nanoparticles with an enhanced cellar uptake as a carrier for bisphosphonates and a method of preparing thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL441261A PL441261A1 (pl) 2022-05-24 2022-05-24 Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania

Publications (1)

Publication Number Publication Date
PL441261A1 true PL441261A1 (pl) 2023-11-27

Family

ID=87158549

Family Applications (1)

Application Number Title Priority Date Filing Date
PL441261A PL441261A1 (pl) 2022-05-24 2022-05-24 Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania

Country Status (2)

Country Link
PL (1) PL441261A1 (pl)
WO (1) WO2023228105A1 (pl)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006102117A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
IT1401882B1 (it) * 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
CN107007552A (zh) * 2017-04-26 2017-08-04 温州医科大学附属口腔医院 一种载抗骨吸收药物纳米颗粒脂‑聚合物的制备方法

Also Published As

Publication number Publication date
WO2023228105A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
Bigi et al. Calcium phosphates as delivery systems for bisphosphonates
He et al. Biomineralization of dentin
Ghosh et al. Self-setting calcium phosphate cements with tunable antibiotic release rates for advanced antimicrobial applications
Chen et al. Biomimetic remineralization of demineralized dentine using scaffold of CMC/ACP nanocomplexes in an in vitro tooth model of deep caries
Yu et al. Strontium-doped amorphous calcium phosphate porous microspheres synthesized through a microwave-hydrothermal method using fructose 1, 6-bisphosphate as an organic phosphorus source: application in drug delivery and enhanced bone regeneration
Nitiputri et al. Nanoanalytical electron microscopy reveals a sequential mineralization process involving carbonate-containing amorphous precursors
Pascaud et al. Adsorption on apatitic calcium phosphates for drug delivery: interaction with bisphosphonate molecules
Kim et al. Biomimetic remineralization as a progressive dehydration mechanism of collagen matrices–implications in the aging of resin–dentin bonds
Iafisco et al. Silica xerogels and hydroxyapatite nanocrystals for the local delivery of platinum–bisphosphonate complexes in the treatment of bone tumors: A mini-review
Cai et al. Chlorhexidine-loaded amorphous calcium phosphate nanoparticles for inhibiting degradation and inducing mineralization of type I collagen
RU2011115356A (ru) Композиция, содержащая ингибирующие кристаллизацию вещества
RU2008102637A (ru) Ионные комплексы
Rothe et al. Adjuvant drug-assisted bone healing: Advances and challenges in drug delivery approaches
RU2009128023A (ru) Фармацевтическая композиция с длительным постепенным высвобождением, содержащая водную суспензию бисфосфоната
MX346469B (es) Control de la textura de composiciones alimenticias altas en proteina que comprenden caseina micelar.
BR112015013539A2 (pt) composições de formação de cimento, cimentos monetita, implantes e métodos para a correção de defeitos de ossos
US20180110899A1 (en) Bone filler composition
BR0110618A (pt) Composição farmacêutica similar a gel para administraçâo subcutânea compreendendo ácidos bis-fosfÈnicos ou seus sais
Roussière et al. Reaction of zoledronate with β-tricalcium phosphate for the design of potential drug device combined systems
Polo et al. Antimicrobial activity of commercial calcium phosphate based materials functionalized with vanillin
Paul et al. In vivo evaluation of injectable calcium phosphate cement composed of Zn‐and Si‐incorporated β‐tricalcium phosphate and monocalcium phosphate monohydrate for a critical sized defect of the rabbit femoral condyle
PL441261A1 (pl) Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania
Linderbäck et al. Sol–gel derived titania coating with immobilized bisphosphonate enhances screw fixation in rat tibia
CA2625975A1 (en) Bishosphonate coated dental implants and methods for producing said implants
Baek et al. Incorporation of calcium sulfate dihydrate into hydroxyapatite microspheres to improve the release of bone morphogenetic protein-2 and accelerate bone regeneration